Jiyya "sofosbuvir": reviews. "Sofosbuvir" + "Daklatasvir": reviews kwararru. "Sofosbuvir": wa'azi da likitoci sake dubawa

Hanta ne nau'i mai tsarkakewa don jikin mutum. Halin jikin nan yana da tasiri akan aiki da tsarin da yawa da kuma rayuwar rayuwar mutum gaba daya. Ɗaya daga cikin lalacewar hanta mafi tsanani shine hepatitis C. A halin yanzu, an yi amfani da kwayoyi masu yawa don yaki da wannan cuta. Ɗaya daga cikin hanyoyin da ya fi tasiri yana dauke (wanda aka tabbatar da shi ta hanyar likita), Sofosbuvir.

Indiya don amfani

Bugu da ƙari, an kira mai haɗin aiki mai aiki a cikin Allunan, kuma alamar kanta tana da sunan kasuwanci "Sowaldi". Saboda haka, shi ne zai yiwu a ce wannan magani mai rahusa canza - Generic "sofosbuvir" wanda sake bitar bayyana da miyagun ƙwayoyi a matsayin daya daga cikin mafi inganci da kwayoyi domin lura da hepatitis C. Wannan shi ne ya main yanki na aikace-aikace.

Babban abu, sophosbuvir, wani mai hanawa ne na polymerase NS5B, watau, yana hana tsarin haifuwa na cutar cutar hepatitis C. Duk da haka, yawancin likitoci ba su bada shawara ga Sofosbuvir monotherapy (ko da yake wannan zai yiwu akan haka). Amma a matsayin babban aiki na maganin cutar maganin rigakafi, likita "Sofosbuvir" yayi la'akari da jagorancin kyakkyawar jagorancin, yana maida shi azaman magani mai mahimmanci. Bisa ga binciken binciken asibitoci, magungunan da ke tare da wasu magunguna sun nuna kyakkyawan sakamako dangane da maganin cutar cutar hepatitis C (kwayoyin 1, 2, 3).

Yin jiyya na Sofosbuvir tare da ma'aikatan kiwon lafiya ya nuna cewa ba kawai ga marasa lafiya wanda ba a taɓa magance su ba, har ma ga waɗanda suka riga sun sami maganin antiviral tare da wasu magunguna kuma, a ƙarshen magani, bayan da aka sake komawa.

Bugu da ƙari da yankin da aka bayyana a sama da aka bayyana, "Sofosbuvir" duba likitoci da shawarwarin shawarwari sun ba da damar yin amfani da maganin marasa lafiya da ke fama da cirrhosis na hanta.

Game da tasiri na miyagun ƙwayoyi don haɗuwa da juna tare da HIV da hepatitis (halin da ake ciki a halin yanzu), wannan bayanin ba a samuwa ba, ko da yake an nuna miyagun ƙwayoyi don amfani a irin wannan yanayi.

Contraindications

A mafi yawan lokuta, marasa lafiyar sunyi maganin miyagun ƙwayoyi da jikinsu.

Duk da haka, miyagun ƙwayoyi don maganin hepatitis C "Sovvaldi" (ko "Sofosbuvir"), wanda sake dubawa yana da tabbacin, kamar kowane magani na yau da kullum, yana da wasu takaddama don amfani.

Na farko, shi ne mutum mai tsaftacewa ga magunguna da magungunan miyagun ƙwayoyi. Mata waɗanda suke da haihuwa suna yin la'akari da yin amfani da shi. Musamman, idan an rubuta "Sowaldi" ("Sofosbuvir") tare da "Ribavirin" da kuma "Interferon alfa" (ainihin ga kwayoyin 3, 4, 5, 6, hepatitis), ya kamata a cikin dukkan hanyoyin da za a iya kauce wa ciki. Har ila yau, marar dacewa don magance wadannan kwayoyi yayin lokacin haihuwa da lokacin lactation.

A halin yanzu, babu wani bayani game da tasirin Sofosbuvir a kan aikin haifa na mutum. Har ila yau babu wani bayani game da aminci da inganci na miyagun ƙwayoyi a marasa lafiya a shekara 18.

Hanyar da tsawon lokacin farfadowa

Da farko, ya kamata a bayyana cewa an ba da izinin maganin antiviral ne kawai ga wadanda ke da ilimin likita wadanda ke da kwarewa sosai wajen magance marasa lafiya tare da hepatitis C. Tsarin tsari shine 1 kwamfutar hannu (400 MG na sashi mai aiki) a yayin rana a kowane lokacin cin abinci. Tun da Allunan suna da zafi (irin wadannan martani daga magunguna da suka karbi magani), "Sofosbuvir" ya kamata a haɗiye shi ba tare da shayewa ba kuma ya karya shi.

Idan aka karbi kwamfutar hannu, bayan haka a cikin sa'o'i 2 na gaba, zubar da jini ya fara, an bada shawarar daukar 1 ƙarin kwamfutar hannu. Idan vomiting tasowa bayan lokaci fiye da sa'o'i 2, ba a buƙatar ƙarin kashi.

Idan an yi amfani da miyagun ƙwayoyi na gaba don kowane dalili ba (lokacin jinkirin ba fiye da awa 18 ba), an bada shawarar daukar nauyin da aka rasa, sa'an nan kuma ci gaba da lura a lokacin da aka saba. Idan jinkirta ya wuce awa 18 - ɗauki kashi na gaba a lokacin da aka saba.

Hanyar hadewa

Yayinda aka gyara magungunan ciwon hawan C, tare da "Sofosbuvir", aikin da ake kira "Ribavirin", "Interferon alfa", "Daklatasvira", "Ladipasvira", "Asunaprevir".

Bugu da ƙari, nazarin lafiyar "Sofosbuvir" + "Daklatasvir" na ma'aikatan kiwon lafiya da marasa lafiya suna da tasiri don yaki da ilimin cutar hepatitis C 1,2,3.

Don kwanan, "Daklatasvir" za a iya ba da umarnin online WWW.ARV24.COM tsĩrar da hannuwanku - a wani kamfanin da dogon-tsaye suna. Ya ba da damar cewa hannayensu suna da cikakken bayani akan kasancewar cutar.

Anyi amfani da kwayoyin 4, 5, 6 tare da hadarin magunguna "Sofosbuvir", "Ribavirin" da "Interferon alfa". Tsarin maganin warkewa yana da akalla makonni 12. A cikin lokuta inda marasa lafiya da kwayoyin 1, 4, 5, 6 suna da takaddama ga shan maganin Interferon alfa ko sasantawa ga wannan abu, Sofosbuvir da Ribavirin an tsara su don shiga cikin makonni 24.

Tasem "Ribavirin" tare da miyagun ƙwayoyi "Sofosbuvir" don nazarin gwanon 2 na masana da aka kwatanta shi ne mafi mahimmanci hade, wanda aka nada don shiga cikin tsawon makonni 12. Magunguna guda biyu, amma har tsawon makonni 24, an yi amfani dasu don samfurin 3 na cutar hepatitis C.

Bayani game da tasiri mai mahimmanci tare da "Ribavirin" da "Interferon" don maganin kwayar halittu 1 bai samuwa ba.

Idan mai ciwo yana shan wahala daga hepatocarcinoma da / ko kuma yana son aiki don haɓaka hanta, ana amfani da "Sofosbuvira" tare da "Ribavirin" don yin makonni 48 ko kuma har sai da zafin jiki don yin gyare-gyare na jikin. Wannan yana da mahimmanci don hana kamuwa da cutar hanta bayan dasawa.

Binciken binciken kwakwalwa ya nuna cewa yin amfani da Sofosbuvir tare da wasu kwayoyi zai iya samar da amsa mai kyau a cikin 92% na lokuta na hadaddun maganin maganin cutar hepatitis C.

Abubuwan sakamako na iya yiwuwa

A lokacin gudanar da gwaji na asibiti, magunguna sunyi haƙuri da kyau sosai (irin wannan ra'ayinsu). "Sofosbuvir" yana haifar da tasiri a mafi yawan lokuta idan aka yi amfani dashi tare da "Ribavirin" da "Interferon".

Lokacin hada Sofosbuvira tare da Ribavirin, maida hankali akan haemoglobin ya rage a cikin jini fiye da sau (fiye da 10% na lokuta) da kuma bilirubin matakan girma, gajiya, rashin tausayi da rashin barci, tashin hankali zai iya faruwa.

Kadan sau da yawa (kasa da kashi 10 cikin dari), wannan haɗuwa da kwayoyi yana haifar da ciwon ciki, anemia, rhinopharyngitis, rashin kulawa da hankali, dyspepsia, rikice-rikice da cututtuka na hanji, rashin bayyanar jiki a kan fata (itching, rashes). Wasu lokuta marasa lafiya sun bar irin wadannan maganganun: "Sofosbuvir", wanda aka yi amfani da shi a layi tare da "Ribavirin", ya sa asarar gashi da ciwon baya, sutures, myalgia da asthenia.

Idan ana amfani da magunguna guda uku (ana amfani da "Interferon-alpha" zuwa biyu waɗanda aka ambata a sama), yawancin abubuwan da ke faruwa mafi banbanci (fiye da 10% na lokuta). A nan suna magana game da canje-canje a cikin jini: yawan karuwar lymphocytes, platelets da neutrophils, anemia, karuwa a matakin bilirubin. Daga tsarin narkewa zai iya haifar da zawo, tashin zuciya, vomiting. Bugu da ƙari, Sofosbuvir (umarni, nazarin marasa lafiya da ma'aikatan kiwon lafiya ya tabbatar) na iya haifar da ciwon kai da kuma rashin hankali, tari, rashin ƙarfi, numfashi da raguwa, myalgia da haɗin gwiwa. Sau da yawa marasa lafiya magana game da gajiya, irritability, jin zafi, zazzabi.

Kadan sau da yawa (daga 1 zuwa 10%) marasa lafiya suna magana game da tsoro da ci gaban ɓacin rai, game da asarar nauyi, game da ƙwaƙwalwar ajiya da ƙananan haɗari, game da migraines. Akwai bayani game da lalacewa na hangen nesa, asarar gashi, ci gaba da reflux da dyspnea tare da karuwa. Wasu lokuta magunguna suna magana ne game da ciwo a baya da kirji, sharaɗi da kuma asthenia.

Menene zan san?

Idan haƙuri yana daya ko fiye korau dalilai - high farko kwayar kaya, fibrosis a cikin wani ci-gaba mataki, ma duhu fatar jiki - da magani daga "sofosbuvir" (reviews masana da kuma umarnin da yadda za a yi amfani da goyan baya) za a iya karu da har zuwa 24 makonni. Lokacin da ake amfani da farfasa, ana amfani da kashi mai kyau na "Ribavirin" bisa ga nauyin jikin mutum, watau 75 kilogiram na nau'in jiki yana buƙatar 1.2 g magani. Dukan ƙwayar miyagun ƙwayoyi ya kasu kashi biyu kuma ana ɗauke ta da abinci.

Ba a bada shawara don rage sashi na "Sofosbuvira" ba.

Idan halayen haɗin gwiwa na Solfosbuvira da Interferon alfa suna nuna alamun bayyanar cututtuka wanda ke da alamun magani na karshe, karɓar maganin Interferon yana buƙatar rage ko sake warware magani (umarnin dalla-dalla akan rage ragewa ko sokewar miyagun ƙwayoyi suna samuwa a cikin umarni na musamman).

Daidai ne daidai lokacin da ake amfani da haɗin "Sofosbuvira" tare da "Ribavirin", da kuma mummunar tasirin da ke ci gaba da karɓar wannan karshen - kashi na rage ko karɓar "Ribavirin" ya ƙare. Bayan sakamakon gwaje-gwajen jini ya inganta, an halatta a sake gwada ci gaba da shan Ribavirin, farawa daga MG 600 kuma ya karu zuwa mita 800. Ba'a bada shawara don ƙara yawan kashi zuwa asalin da aka tsara ba.

Idan ka soke daya daga cikin magungunan maganin magunguna, ya kamata ka daina karbar "Sofosbuvir" gaba daya - maganganun kwararru da umarnin da ake amfani dasu a cikin wannan matsala sun kasance iri ɗaya.

Saduwa da wasu abubuwa

Ma'aikatan kiwon lafiya ba su bayar da shawarar marasa lafiya a cikin layi daya tare da miyagun ƙwayoyi da ake tambaya don amfani da wasu kwayoyi masu maganin rigakafi (banda wadanda aka tsara ta likitan likita) a lokacin da aka kula da cutar hepatitis. Binciken "Sofosbuvir" na kwararru sunyi la'akari da yiwuwar hadawa tare da wani abu dabam kawai a cikin waɗannan lokuta idan amfanin da aka sa ran daga haɗuwa da kwayoyi ya wuce yiwuwar hadarin da ba'a so ba.

Akwai wasu magungunan kwayoyi, haɗin haɗin gwiwa tare da Sofosbuvir zai iya rage yawanta ("Sofosbuvira") a cikin hanji. Ga waɗannan maganin - daga anticonvulsants - yana yiwuwa a ɗaukar "Phenytoin", "Phenobarbital", "Carbamazepine" da "Oxcarbazepine". Magungunan antimycobacterial na magunguna kuma sun ƙunshi irin wadannan kwayoyi: Rifabutin, Rifampicin, Rifapentin. Daga kayan daji na kayan lambu, yana yiwuwa ya rage rage Sofosbuvira ta hanyar St. John's Wort. Har ila yau ba a bada shawara don hada magunguna tare da masu hanawa protease HIV: "Tipranavir", "Ritonavir".

Umurni na musamman

Kwararren likitanci yana da hakkin ya zaɓi tsarin kulawa don cutar hepatitis C da magunguna da za a ba da izini ga magani: "Ladipasvir", "Asunaprevir", "Sofosbuvir", "Daklatasvir". Binciken marasa lafiya na dukan janar na "Sovvaldi" suna da kyau.

Duk da haka, ya kamata a tuna cewa ga marasa lafiya da siffofin ƙananan ƙwayar cuta, za a zaɓi ƙarar kashi a musamman. Babu buƙatar sake gwada sashi ga wadanda ke fama da rashin lafiya da matsakaici. Amma ga rashin lafiya na asibiti, babu buƙatar daidaita yanayin ga marasa lafiya da kowane mataki na rashin lafiya.

A lura da hepatitis C tare da yin amfani da farfadowa a kan "Sofosbuvira" ba a ba da shawarar yin aiki a cikin ayyukan da suke buƙatar haɗakarwa da hankali da kuma karfin halayen psychomotor.

Farashin farashin

Kudin magungunan da aka yi amfani da ita a Jamus ya kasance daga tamanin 18 zuwa 20,000. Kuma don sayen shi, koda a wannan farashi, zaka buƙaci takardar sayan magani daga likitan mai magani. Irin wannan farashi mai yawa ne saboda gaskiyar cewa kamfanin haɓaka zai sake kwashe dukiyarsa don binciken kimiyya, ci gaba da gwaji na magunguna.

Yana da yawa mai rahusa don biyan magungunan ƙwayoyin magungunan ƙwayar magungunan (ƙananan analogues na alama tare da nau'in aiki mai mahimmanci). Wadannan sun hada da "Daklatasvir", "Asunaprevir", "Ladipasvir" da "Sofosbuvir". Kasuwancin masu amfani sun ƙunshi bayani game da yawan kuɗin da waɗannan magungunan suka yi, amma ba kimanin dubban kudin Tarayyar Turai ba.

An fara ne a cikin watan Maris na 2015, bisa ga lasisi na kamfanin haɓaka, sakin Sofosbuvira ya fara ne daga kamfanin Natko na kamfanin Indiya (bisa ga izinin Ma'aikatar Lafiya na Indiya).

A halin yanzu, a Rasha yana yiwuwa a sayi kunshin (28 allunan) na magani "Sofosbuvir" a farashin 39,900 rubles (1 kwamfutar hannu zai kai kimanin 1800 rubles). Wannan ba dadi ba ne, amma daidai wannan buƙatar rubutun da ake kira "Sowaldi" zai buƙaci zuba jarurruka na kudi a adadin 1,500,000 rubles, wanda kusan kusan sau 35 ya fi tsada fiye da kowane nau'i.

Ta hanyar zane-zane, babu wata hanya ta saya wannan magani, tun lokacin da ake aiwatar da takaddun shaida na sababbin magunguna a Rasha ya wuce.

Bayani ga masu amfani da likitoci

Magunguna sunyi maganin miyagun ƙwayoyi da kwayoyin cutar hepatitis daban-daban, nau'o'in fibrosis, tare da transaminases wanda ya fi girma fiye da al'ada, kuma, a matsayin mai mulkin, babban nauyin hoto.

Mafi yawan marasa lafiya da ke shan maganin miyagun ƙwayoyi suna barin bayani masu kyau game da miyagun ƙwayoyi na Sofosbuvir. Wanda aka bi (lokutta yawancin irin wannan bayani) a baya daga cikin interferons na hepatitis C, ya nuna cewa kwayoyi ba za a iya kwatanta su ba. Interferons suna haifar da sakamako mai yawa, kuma ba dukkan marasa lafiya suna da ƙarfin ƙarfin hali ba. Game da haɗin Sofosbuvir da Daklatasvir (mafi yawan marasa lafiya suna magana akan wannan tayin), ƙananan ƙananan waɗanda aka bi da waɗannan kwayoyi sunyi magana game da ci gaba da ƙananan cututtuka a cikin nau'i-nau'i, matsananciyar ciwon kai da kuma hasara na gajeren lokaci. Duk da haka, waɗannan alamu ba za a iya kwatanta su tare da maganganu na Interferon da sakamakon cutar hepatitis kanta ba. Bayan makonni 2-3 na farfadowa, abun ciki na transaminases a cikin hanta ya zuwa al'ada a cikin marasa lafiya. Tun da makonni uku na magani tare da hadaddun kwayoyi masu maganin kwayar cutar "Sofosbuvir" da "Daklatasvir" a cikin marasa lafiya da yawa, sakamakon da cutar cutar hepatitis C ta ke cikin jiki bata da kyau.

Har ila yau, yawancin marasa lafiya suna nuna raguwa mai yawa a cikin fibrosis bayan watanni da yawa na farfadowa.

Wadannan masu amfani da suka dauki magungunan maganin magunguna guda uku - Sofosbuvir, Daklatasvir, da kuma Ribaverine - sun kasance da farin ciki da sakamakon maganin.

Kusan dukkan masu amfani da Sofosbuvir sunyi magana game da ainihin nasara a maganin maganin cutar hepatitis C idan aka kwatanta da maganin interferon. Ƙara ingantaccen kiwon lafiya da ingancin rayuwar marasa lafiya - wannan hujja ce ta gaskiya.